News Miriam Corredor, CEO of noctuRNA: “Thanks to the support of CDTI Innovation we are promoting a new generation of therapies based on circRNA” NoctuRNA drives, thanks to the CDTI, a new generation of RNA-based therapies Miriam Corredor: “The goal of noctuRNA Therapeutics is to offer innovative therapeutic solutions for diseases that currently have no cure” NoctuRNA Therapeutics is born, a spin-off from UPF that develops new antivirals based on an RNA platform
